Impel NeuroPharma (NASDAQ: IMPL) shares are down premarket on Friday after it announced its $45 million public offering pricing.
The company is offering 3 million shares of its stock at a price of $15 per share. Before deducting expenses, the gross proceeds from the offering are expected to be $45.0 million.
In addition, Impel has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of stock at the offering price. The offering is expected to close on September 14.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Cowen and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Thursday saw the company’s shares gain 27.25%, closing at $21.13 a day after it announced the public offering.
However, premarket on Friday has seen Impel shares resume their fall, currently trading at $18.35, down 13.87%
Only last week, Cowen analyst Ken Cacciatore raised the firm’s price target on Impel NeuroPharma to $55 from $35, keeping an Outperform rating.
Should You Invest in Impel NeuroPharma Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now